EUSA Pharma (UK) Ltd.
http://www.eusapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From EUSA Pharma (UK) Ltd.
Ligand Makes Second Big Oncology Investment In 2024 With Apeiron Buyout
The company is acquiring rights to royalties from Qarziba, a neuroblastoma drug approved in ex-US markets that Recordati develops and markets in all of them except mainland China.
Essential Emerges As A Drug Developer With Renaissance Buy
The acquisition of Renaissance and its promising Phase III-ready asset for neuroblastoma could be the first of a number of deals in the near future, Essential CEO Emma Johnson tells Scrip.
China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.
Recordati Expands Into Rare Cancer Space With EUSA Pharma Buy
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice